Data privacy-aware machine learning approach in pancreatic cancer diagnosis
Open Access
- 5 September 2024
- journal article
- research article
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 24 (1) , 1-14
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is considered a highly lethal cancer due to its advanced stage diagnosis. The five-year survival rate after diagnosis is less than 10%. However, if diagnosed early, the five-year survival rate can reach up to 70%. Early diagnosis of PDAC can aid treatment and improve survival rates by taking necessary precautions. The challenge is to develop a reliable, data privacy-aware machine learning approach that can accurately diagnose pancreatic cancer with biomarkers. The study aims to diagnose a patient’s pancreatic cancer while ensuring the confidentiality of patient records. In addition, the study aims to guide researchers and clinicians in developing innovative methods for diagnosing pancreatic cancer. Machine learning, a branch of artificial intelligence, can identify patterns by analyzing large datasets. The study pre-processed a dataset containing urine biomarkers with operations such as filling in missing values, cleaning outliers, and feature selection. The data was encrypted using the Fernet encryption algorithm to ensure confidentiality. Ten separate machine learning models were applied to predict individuals with PDAC. Performance metrics such as F1 score, recall, precision, and accuracy were used in the modeling process. Among the 590 clinical records analyzed, 199 (33.7%) belonged to patients with pancreatic cancer, 208 (35.3%) to patients with non-cancerous pancreatic disorders (such as benign hepatobiliary disease), and 183 (31%) to healthy individuals. The LGBM algorithm showed the highest efficiency by achieving an accuracy of 98.8%. The accuracy of the other algorithms ranged from 98 to 86%. In order to understand which features are more critical and which data the model is based on, the analysis found that the features “plasma_CA19_9”, REG1A, TFF1, and LYVE1 have high importance levels. The LIME analysis also analyzed which features of the model are important in the decision-making process. This research outlines a data privacy-aware machine learning tool for predicting PDAC. The results show that a promising approach can be presented for clinical application. Future research should expand the dataset and focus on validation by applying it to various populations.Keywords
This publication has 39 references indexed in Scilit:
- Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and ChallengesInternational Journal of Molecular Sciences, 2023
- Federated auto-encoder and XGBoost schemes for multi-omics cancer detection in distributed fog computing paradigmChemometrics and Intelligent Laboratory Systems, 2023
- A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on 18F-FDG PET/CT imagesJapanese Journal of Radiology, 2022
- Making data visualization more efficient and effective: a surveyThe VLDB Journal, 2019
- Data science, artificial intelligence, and machine learning: Opportunities for laboratory medicine and the value of positive regulationClinical Biochemistry, 2019
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomesWorld Journal of Gastroenterology, 2018
- Pancreatic cancerThe Lancet, 2016
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Data Pre-processing2013
- Recent progress in urinary proteomicsProteomics – Clinical Applications, 2007